Patents by Inventor Cuong Ly
Cuong Ly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11807626Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.Type: GrantFiled: April 22, 2021Date of Patent: November 7, 2023Assignee: Opna Bio SAInventors: Songyuan Shi, John Buell, Zuojun Guo, Cuong Ly, Wayne Spevak, Mark Vander Wal, Jack Walleshauser, Chao Zhang, Jiazhong Zhang
-
Patent number: 11689412Abstract: Disclosed herein are system, method, and computer program product embodiments for determining monitoring compliance for an enterprise application deployed on an application delivery platform. Existing resources, monitors and alerts are discovered with gaps in monitoring being calculated based on a comparison of monitoring objectives and the existing monitors and alerts. Gaps in monitoring are reported in a GUI reflecting effectiveness of existing monitors.Type: GrantFiled: August 4, 2021Date of Patent: June 27, 2023Assignee: Capital One Services, LLCInventors: Prasad Konduri, Kadhiresan Kanniyappan, Manohar Malapati, Cory Williams, Kevin P. Poffenberger, Aruna Alla, Bhaskar Banerjee, Joseph Knight, Cuong Ly, Patrick Barnes, Elijah Carter, Srinivasan Subramanian, Paul Pelayo, Raghava Bidathanapalli, Priyanka Kulkarni
-
Publication number: 20230039822Abstract: Disclosed herein are system, method, and computer program product embodiments for determining monitoring compliance for an enterprise application deployed on an application delivery platform. Existing resources, monitors and alerts are discovered with gaps in monitoring being calculated based on a comparison of monitoring objectives and the existing monitors and alerts. Gaps in monitoring are reported in a GUI reflecting effectiveness of existing monitors.Type: ApplicationFiled: August 4, 2021Publication date: February 9, 2023Applicant: Capital One Services, LLCInventors: Prasad KONDURI, Kadhiresan KANNIYAPPAN, Manohar MALAPATI, Cory WILLIAMS, Kevin P. POFFENBERGER, Aruna ALLA, Bhaskar BANERJEE, Joseph KNIGHT, Cuong LY, Patrick BARNES, Elijah CARTER, Srinivasan SUBRAMANIAN, Paul PELAYO, Raghava BIDATHANAPALLI, Priyanka KULKARNI
-
Publication number: 20220144805Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.Type: ApplicationFiled: April 22, 2021Publication date: May 12, 2022Inventors: Songyuan Shi, John Buell, Zuojun Guo, Cuong Ly, Wayne Spevak, Mark Vander Wal, Jack Walleshauser, Chao Zhang, Jiazhong Zhang
-
Patent number: 10968203Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: May 24, 2018Date of Patent: April 6, 2021Assignees: Genentech, Inc., The Regents of the University of CaliforniaInventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
-
Patent number: 10647731Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.Type: GrantFiled: April 25, 2018Date of Patent: May 12, 2020Assignee: Genentech, Inc.Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
-
Patent number: 10392422Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: August 27, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Patent number: 10351595Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: July 16, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Publication number: 20180265497Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: May 24, 2018Publication date: September 20, 2018Applicants: Genentech, Inc., The Regents of the University of CaliforniaInventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
-
Publication number: 20180244694Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.Type: ApplicationFiled: April 25, 2018Publication date: August 30, 2018Applicant: Genentech, Inc.Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
-
Patent number: 9988400Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.Type: GrantFiled: April 8, 2016Date of Patent: June 5, 2018Assignee: Genentech, Inc.Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
-
Publication number: 20170088582Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: May 19, 2015Publication date: March 30, 2017Applicants: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, Prasuna PARASELLI, Philippe BERGERON, Michael F.T. KOEHLER, Huiyong HU, Jacob Bradley SCHWARZ, Cuong LY, James CRAWFORD
-
Publication number: 20160222033Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.Type: ApplicationFiled: April 8, 2016Publication date: August 4, 2016Applicant: Genentech, Inc.Inventors: Jiang Yu, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Volgraf Matthew
-
Patent number: 9399636Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.Type: GrantFiled: November 21, 2014Date of Patent: July 26, 2016Assignee: Genentech, Inc.Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
-
Patent number: 9040706Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3, R4, R4?, R5, R6 and R6? are as described herein.Type: GrantFiled: November 22, 2013Date of Patent: May 26, 2015Assignee: GENENTECH, INC.Inventors: Frederick Cohen, Vickie Hsiao-Wei Tsui, Cuong Ly, John A. Flygare
-
Publication number: 20150080367Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.Type: ApplicationFiled: November 21, 2014Publication date: March 19, 2015Applicant: Genentech, Inc.Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
-
Publication number: 20140080805Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3, R4, R4?, R5, R6 and R6? are as described herein.Type: ApplicationFiled: November 22, 2013Publication date: March 20, 2014Applicant: Genentech, Inc.Inventors: Frederick COHEN, Vickie Hsiao-Wei TSUI, Cuong LY, John A. FLYGARE
-
Patent number: 8609845Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3, R4, R4?, R5, R6 and R6? are as described herein.Type: GrantFiled: August 10, 2009Date of Patent: December 17, 2013Assignee: Genentech, Inc.Inventors: Frederick Cohen, Vickie Hsiao-Wei Tsui, Cuong Ly, John A. Flygare
-
Patent number: 8163763Abstract: Disclosed are compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).Type: GrantFiled: July 31, 2009Date of Patent: April 24, 2012Assignee: Genentech, Inc.Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F. T. Koehler, Kevin Hon Luen Lau, Cuong Ly, Joseph P. Lyssikatos, Daniel Ortwine, Zhonghua Pei, Xianrui Zhao
-
Publication number: 20100331305Abstract: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).Type: ApplicationFiled: June 23, 2010Publication date: December 30, 2010Applicant: Genentech, Inc.Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F.T. Koehler, Cuong Ly, Joseph P. Lyssikatos, Zhonghua Pei, Wendy Lee, Xianrui Zhao